Immuron Limited (IMRN)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20265 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Immuron Limited’s names, not what it holds today.
6 published
1 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Dec 4, 2018 | 10,144,775 | Methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease | Pharmaceuticals | IMMURON LIMITED |
| Nov 6, 2018 | 10,117,930 | Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder | Pharmaceuticals | IMMURON LIMITED |
| Apr 17, 2018 | 9,943,597 | Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder | Pharmaceuticals | IMMURON LIMITED |
| Aug 2, 2016 | 9,402,902 | Composition and method for the treatment and prevention of enteric bacterial infections | Medical technology | IMMURON LIMITED |
| Jan 28, 2014 | 8,637,025 | Composition and method for the treatment and prevention of enteric bacterial infections | Pharmaceuticals | IMMURON LIMITED |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.